An interventional study of Class 2 compression stockings in Varicose Veins, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-05.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
This study will be looking at the effect of compression therapy in patients having endovenous treatment for varicose veins using foam sclerotherapy. Patients will be randomised to either the compression group (group A) or the no compression group (group B).
The pain scores, compliance, quality of life scores, occlusion rate at 6 months as well as the cost effectiveness of each intervention will be assessed.
This will be a randomised clinical trial looking at the impact of wearing or not wearing compression stocking following endovenous ablation using foam sclerotherapy.
Patients will be randomised to group A (compression) and group B (no compression).
Target Population Patients referred to the Imperial College NHS Trust for treatment of symptomatic varicose veins will be recruited if they are found to have varicose veins suitable for foam sclerotherapy on colour duplex scan.
Intervention
Patients will be randomised to have compression (group A) or no compression (group B). This will be done by using an online randomisation software (Sealed Envelope Ltd).
The compression therapy used will be Class II compression stockings. The treatment offered will be foam sclerotherapy of varicose veins using either Polidocanol or Sodium Tetradecyl Sulphate (STS) with the concentration used left to the discretion of the clinician.
Patients randomised to group A will be asked to wear compression stockings for 1 week.
Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards.
At baseline, patients will be asked to fill validated quality of life questionnaires (EQ-5D, AVVQ and CIVIQ) and will have their clinical scores assessed using a validated scoring system (CEAP and VCSS). On discharge after their varicose vein intervention, they will then be provided with a diary to record their post-procedural pain every day for 10 days using a validated visual analogue scale (VAS) as well as to record when they return to their normal activities and are back to work. They will also be asked to attend a follow-up in 2 weeks and at 6 months.
Patients' GP will also be sent a letter to inform them of their patient's participation in the study.
Follow-up
Patients will be followed up in the outpatient clinic at 2 weeks and 6 months.
Follow-up at 2 Weeks
At the 2 weeks' follow-up, the diary containing details of the pain scores and how soon patients were able to return to normal activities/work will be collected. In addition, patients will be asked about any phlebitis they have had in the two weeks after their procedure and how compliant they have been with the compression. They will be examined and the Venous Clinical Severity Score (VCSS) will be recorded. They will also be asked to fill in the EQ-5D, AVVQ and CIVIQ scores.
Follow-up at 6 Months
At the 6 months follow-up, patients will be examined and their VCSS will be recorded. They will also be asked to fill the EQ-5D, AVVQ and the CIVIQ scores. They will have a venous Duplex scan to determine occlusion of the treated vein.
Sample Size and Study Duration
We estimated the sample size needed to observe a difference of at least 10mm in the VAS score, with a standard deviation of 20mm. With power at 80% and 5% significance equivalence, we would need to recruit 128 patients (64 per group) to show a difference.
Previous studies looking at compression stockings have shown drop out rates close to 37% at 3 months10. Therefore, if we estimate a drop out rate of about 40% by 6 months, we would need to recruit at least 180 patients. If we recruit at least 2 patients per week, this will be approximately a total of 208 patients that could potentially be randomised over the course of two years.
With 6 months follow-up, therefore, the study will be running for 24 months with a target recruitment of 180 patients.
258 studies on the registry are indexed under Varicose Veins; 36 are open to participants now.
This study's planned enrollment of 180 is above the median of 104 across 165 interventional studies indexed under Varicose Veins.
Browse Varicose Veins studies →Imperial College London is the lead sponsor of 842 studies on the registry; 180 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients randomised to group A will be asked to wear compression stockings for 1 week
Other: Class 2 compression stockings
Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards
Patient's pain score post-procedure using a visual analogue scale (VAS)
Pain score
Time frame: 10 days
Aberdeen Varicose Vein Questionnaire (AVVQ) score
Disease-specific quality of life score
Time frame: 6 months
Chronic venous insufficiency (CIVIQ) score
Disease-specific quality of life score
Time frame: 6 months
EuroQol's EQ-5D
Generic quality of life score
Time frame: 6 months
Venous clinical severity score (VCSS)
Clinical
Time frame: 6 months
Occlusion rate
Occlusion rates will be assessed based on a pre-agreed scale
Time frame: 6 months
Degree of phlebitis
Extent of phlebitis will be recorded using a scale
Time frame: 6 months
Plan to share: No
Ran from Jan 2016 to primary completion in Jan 2020, 48 months.
Of 72 non-industry interventional studies with no phase under Varicose Veins, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's 48 months is above that.
Counting every sponsor, half of 81 studies reached it within 23 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.